Potential of Nanocarrier-Based Drug Delivery Systems for Brain Targeting: A Current Review of Literature

Alotaibi, Badriyah; Buabeid, Manal; Ibrahim, Nihal Abdalla; Kharaba, Zelal; Ijaz, Munazza; Noreen, Sobia; Murtaza, Ghulam

doi:10.2147/ijn.s333657

Cited by 43 publications

(20 citation statements)

References 140 publications

(178 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

Section: Improved Pharmacokinetics and Bioactivity Of Nmc Delivery Sy...mentioning

confidence: 99%

“…The mechanism by which nanoparticles penetrate the BBB is still not very clear. Currently, the relative theories are listed as follows ( Morad et al, 2019 ; Akel et al, 2021 ; Alotaibi et al, 2021 ; Han and Jiang, 2021 ; Hou et al, 2022 ): 1) The phagocytosis of nanoparticles by cerebral vascular endothelial cells allows the drug to be released and diffused into the brain; 2) The adsorption of capillary walls prolongs the residence time of drugs in the brain, thereby increases the amount of drugs entering the brain; 3) Nanoparticles open the tight junctions of capillary epithelial cells, and drugs penetrate into the brain from the open gaps; 4) The effect of some modifications of nanoparticles such as polysorbate 80, can efficiently inhibit the efflux pump p-gp glycoprotein. Rutin-encapsulated chitosan nanoparticles were fabricated via an ionic gelation method.…”

Section: Improved Pharmacokinetics and Bioactivity Of Nmc Delivery Sy...mentioning

confidence: 99%

See 1 more Smart Citation

Better Bioactivity, Cerebral Metabolism and Pharmacokinetics of Natural Medicine and Its Advanced Version

et al. 2022

View full text Add to dashboard Cite

Currently, many people are afflicted by cerebral diseases that cause dysfunction in the brain and perturb normal daily life of people. Cerebral diseases are greatly affected by cerebral metabolism, including the anabolism and catabolism of neurotransmitters, hormones, neurotrophic molecules and other brain-specific chemicals. Natural medicines (NMs) have the advantages of low cost and low toxicity. NMs are potential treatments for cerebral diseases due to their ability to regulate cerebral metabolism. However, most NMs have low bioavailability due to their low solubility/permeability. The study is to summarize the better bioactivity, cerebral metabolism and pharmacokinetics of NMs and its advanced version. This study sums up research articles on the NMs to treat brain diseases. NMs affect cerebral metabolism and the related mechanisms are revealed. Nanotechnologies are applied to deliver NMs. Appropriate delivery systems (exosomes, nanoparticles, liposomes, lipid polymer hybrid nanoparticles, nanoemulsions, protein conjugation and nanosuspensions, etc.) provide better pharmacological and pharmacokinetic characteristics of NMs. The structure-based metabolic reactions and enzyme-modulated catalytic reactions related to advanced versions of NMs alter the pharmacological activities of NMs.

show abstract

Section: Improved Pharmacokinetics and Bioactivity Of Nmc Delivery Sy...mentioning

confidence: 99%

Section: Improved Pharmacokinetics and Bioactivity Of Nmc Delivery Sy...mentioning

confidence: 99%

Better Bioactivity, Cerebral Metabolism and Pharmacokinetics of Natural Medicine and Its Advanced Version

et al. 2022

View full text Add to dashboard Cite

show abstract

“…For example, due to the ultrasmall size and good biocompatibility, carbon-based nanomaterials including carbon nanodots have been applied as potential BBB-penetrating vectors. 19,21 Moreover, the BBB penetration performance of carbon-based nanomaterials can be enhanced by photothermal response properties. However, nanomaterials that break through the BBB still need to be further optimized and improved.…”

Section: Introductionmentioning

confidence: 99%

Multifunctional Carbon-Dot-Photosensitizer Nanoassemblies for Inhibiting Amyloid Aggregates, Suppressing Microbial Infection, and Overcoming the Blood–Brain Barrier

Yan

Wang

Shao

et al. 2022

ACS Appl. Mater. Interfaces

View full text Add to dashboard Cite

Amyloid aggregation, microbial infection, and the blood−brain barrier (BBB) are considered critical obstructions for the treatment of Alzheimer's disease (AD). At present, existing treatment strategies are rarely able to overcome these critical factors. Herein, we propose an innovative treatment strategy and design multifunctional nanoassemblies (yCDs-Ce6) from coassembling photosensitizers (chlorine e6) and yellow fluorescent carbon dots, which endow yCDs-Ce6 with the functions for photodynamic and photothermal therapy (PDT and PTT). Compared with reported inhibitors, yCDs-Ce6 can suppress amyloid aggregation for 7 days, disaggregate aggregates, reduce amyloid aggregation-induced cytotoxicity, and prevent microbial growth by PDT and PTT. Moreover, yCDs-Ce6 can specifically target amyloid aggregates and visually label amyloid aggregates. yCDs-Ce6 can also cross the BBB upon near-infrared light irradiation and clear amyloid deposition in APP/PS1 mice by PDT and PTT. Meanwhile, yCDs-Ce6 did not cause significant negative effects on normal cells or tissues. Based on the methods of PPT and PTT treatment, the research deeply explores the effect of the novel nanoassemblies on two hypotheses of AD, opening a novel therapeutic paradigm for research amyloid-related diseases.

show abstract

“…In addition, nanomedicines could carry drugs across the BBB and reduce nonspecific accumulation with the modification of targeting ligand (Pinheiro et al, 2021). With the development of targeting delivery technology, researchers have paid more attention to the secondary targeting effect of nanomedicines after crossing the BBB, specifically targeting specific cells or even organelles at the subcellular level (Alotaibi et al, 2021). What is more, the design of functional materials enables on‐demand drug release in specific disease micro‐environments.…”

Section: Introductionmentioning

confidence: 99%

Brain‐targeting drug delivery systems

Liu

Jiang

2022

WIREs Nanomed Nanobiotechnol

View full text Add to dashboard Cite

Brain diseases, including neurodegenerative diseases, acute ischemic stroke and brain tumors, have become a major health problem and a huge burden on society with high morbidity and mortality. However, most of the current therapeutic drugs can only relieve the symptoms of brain diseases, and it is difficult to achieve satisfactory therapeutic effects fundamentally. Extensive studies have shown that the therapeutic effects of brain diseases are mainly affected by two factors: the conservation of the blood–brain barrier (BBB) and the complexity of the brain micro‐environment. Brain‐targeting drug delivery systems provide new possibilities for overcoming these barriers with versatility. In this review, it provides an overview of BBB alteration and discusses targeting delivery strategies for brain diseases therapy. Furthermore, delivery systems which are designed to modulate the brain micro‐environment with synergistic effects were also highlighted. This article is categorized under: Therapeutic Approaches and Drug Discovery > Emerging Technologies

show abstract

Potential of Nanocarrier-Based Drug Delivery Systems for Brain Targeting: A Current Review of Literature

Cited by 43 publications

References 140 publications

Better Bioactivity, Cerebral Metabolism and Pharmacokinetics of Natural Medicine and Its Advanced Version

Better Bioactivity, Cerebral Metabolism and Pharmacokinetics of Natural Medicine and Its Advanced Version

Multifunctional Carbon-Dot-Photosensitizer Nanoassemblies for Inhibiting Amyloid Aggregates, Suppressing Microbial Infection, and Overcoming the Blood–Brain Barrier

Brain‐targeting drug delivery systems

Contact Info

Product

Resources

About